Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care.

Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

Why Health Systems Are Turning to Cancerguard for Early Cancer Detection

The healthcare industry’s leading source for news, intelligence, and strategy for senior executives.

Why Health Systems Are Turning to Cancerguard for Early Cancer Detection

HealthLeaders Podcast